A multicenter, randomized phase III study comparing a 13.5 mg levonorgestrel intrauterine contraceptive system with a combined oral contraceptive: analysis of user satisfaction and safety

• L. Borgatta, K. Roth, S. Rybowski, K. Rosen

• Fertility and Sterility, September 2014, Elsevier
• DOI: 10.1016/j.fertnstert.2014.07.048